FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1594-1599 June 15, 1995 Number 24 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Congenital osteopetrosis is a rare osteosclerotic bone disease characterized by both a defect in osteoclastic function and reduced generation of superoxide by leukocytes. The disease is frequently fatal during the first decade of life. A six-month trial of therapy with recombinant human interferon gamma-1b in eight patients with osteopetrosis provided evidence of benefit, prompting this study of more prolonged therapy.

Methods We studied 14 patients with severe osteopetrosis treated with subcutaneous injections of recombinant human interferon gamma-1b (1.5 µg per kilogram of body weight per dose) three times per week for at least 6 months; 11 patients were treated for 18 months. We assessed the effect of therapy by evaluating the patients' clinical status, measuring blood counts and biochemical markers of bone turnover, and performing bone marrow imaging and bone biopsies.

Results After 6 months of therapy, all 14 patients had decreases in trabecular-bone area (determined by histomorphometric analysis of bone-biopsy specimens) and increases in bone marrow space (determined by marrow imaging), and the improvement was sustained in the 11 patients treated for 18 months. The mean (±SD) hemoglobin concentration increased from 7.5±2.9 to 10.5±0.3 g per deciliter (P = 0.05), and superoxide generation by granulocyte–macrophage colonies increased (P<0.001) after 18 months of therapy. In six patients for whom pretreatment data were available, there was a 96 percent decrease in the frequency of infections requiring antibiotic therapy during interferon treatment. There were no side effects necessitating the discontinuation of therapy.

Conclusions Long-term therapy with interferon gamma in patients with osteopetrosis increases bone resorption and hematopoiesis and improves leukocyte function.

Source Information

From the Departments of Pediatric Endocrinology (L.L.K., R.M.R., S.M.W., N.M.W., H.C.H., W.L.R.), Radiology (J.K.C.), and Orthopedics (P.P.G.), the Medical University of South Carolina, Charleston; and the Department of Orthopedics, University of Washington, Seattle (D.R.E.).

Address reprint requests to Dr. Key at the Department of Pediatric Endocrinology, CSB316E, 96 Jonathan Lucas Ave., Medical University of South Carolina, Charleston, SC 29425-2248.

Full Text of this Article

This article has been cited by other articles:

• Lorenzo, J., Horowitz, M., Choi, Y. (2008). Osteoimmunology: Interactions of the Bone and Immune System. Endocr. Rev. 29: 403-440 [Abstract] [Full Text]  
• Landa, J., Margolis, N., Di Cesare, P. (2007). Orthopaedic Management of the Patient With Osteopetrosis. J Am Acad Orthop Surg 15: 654-662 [Abstract] [Full Text]  
• Lissat, A., Vraetz, T., Tsokos, M., Klein, R., Braun, M., Koutelia, N., Fisch, P., Romero, M. E., Long, L., Noellke, P., Mackall, C. L., Niemeyer, C. M., Kontny, U. (2007). Interferon-{gamma} Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity. Am. J. Pathol. 170: 1917-1930 [Abstract] [Full Text]  
• Lopez, M. N., Pereda, C., Ramirez, M., Mendoza-Naranjo, A., Serrano, A., Ferreira, A., Poblete, R., Kalergis, A. M., Kiessling, R., Salazar-Onfray, F. (2007). Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy. IOVS 48: 1219-1227 [Abstract] [Full Text]  
• Thomas, B, Elias-Jones, A C, Sridhar, A V (2006). A newborn twin with unusual chest radiograph. Postgrad. Med. J. 82: e28-e28 [Full Text]  
• Garcia-Perez, M.A., Noguera, I., Hermenegildo, C., Martinez-Romero, A., Tarin, J.J., Cano, A. (2006). Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. Hum Reprod 21: 880-887 [Abstract] [Full Text]  
• Gao, Y., Qian, W.-P., Dark, K., Toraldo, G., Lin, A. S. P., Guldberg, R. E., Flavell, R. A., Weitzmann, M. N., Pacifici, R. (2004). Estrogen prevents bone loss through transforming growth factor {beta} signaling in T cells. Proc. Natl. Acad. Sci. USA 101: 16618-16623 [Abstract] [Full Text]  
• Strieter, R. M., Starko, K. M., Enelow, R. I., Noth, I., Valentine, V. G., the other members of the Idiopathic Pulmonary Fibr, (2004). Effects of Interferon-{gamma} 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 170: 133-140 [Abstract] [Full Text]  
• Wilson, C J, Vellodi, A (2000). Personal practice: Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch. Dis. Child. 83: 449-452 [Full Text]  
• Burt, N., Haynes, G. R., Bailey, M. K. (1999). Patients with Malignant Osteopetrosis Are at High Risk of Anesthetic Morbidity and Mortality. Anesth. Analg. 88: 1292-1292 [Abstract] [Full Text]  
• Valente, A. J., Xie, J.-f., Abramova, M. A., Wenzel, U. O., Abboud, H. E., Graves, D. T. (1998). A Complex Element Regulates IFN-{gamma}-Stimulated Monocyte Chemoattractant Protein-1 Gene Transcription. J. Immunol. 161: 3719-3728 [Abstract] [Full Text]  
• Stocks, R. M. S., Wang, W. C., Thompson, J. W., Stocks II, M. C., Horwitz, E. M. (1998). Malignant Infantile Osteopetrosis: Otolaryngological Complications and Management. Arch Otolaryngol Head Neck Surg 124: 689-694 [Abstract] [Full Text]  
• Whyte, M. P. (1995). Chipping Away at Marble-Bone Disease. NEJM 332: 1639-1640 [Full Text]  
• Yang, S., Madyastha, P., Bingel, S., Ries, W., Key, L. (2001). A New Superoxide-generating Oxidase in Murine Osteoclasts. J. Biol. Chem. 276: 5452-5458 [Abstract] [Full Text]